article thumbnail

Covid-19 induced immune response may damage brain, NINDS study finds

Pharmaceutical Technology

Scientists at the National Institutes of Health (NIH) unit National Institute of Neurological Disorders and Stroke (NINDS) have found that Covid-19-induced immune response could damage the blood vessels of the brain and may lead to short and long-term neurological symptoms. .

article thumbnail

Molecular change to immunotherapy antibody could accelerate immune response to cancer

Medical Xpress

This also happens in our body, in driving an immune response. Like human drivers, antibodies have a "foot"—a sort of molecular limb that "presses" the gas and brake pedals. And as far as these cancer-fighting antibodies are concerned, speed is of the essence.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Intranasal delivery of AstraZeneca COVID-19 vaccine fails to generate strong immune response

BioPharma Reporter

Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today.

article thumbnail

Atrium Health gets grant for cancer treatment using antibodies and engineered cytotoxic cells

Pharmaceutical Technology

Discover how Atrium Health's groundbreaking patent revolutionizes cancer treatment with targeted antibodies and cytotoxic cells, enhancing immune response and improving patient outcomes.

Antibody 130
article thumbnail

Innovation in immuno-oncology: Leading companies in cancer monoclonal antibody therapy

Pharmaceutical Technology

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.

Antibody 261
article thumbnail

Study: Antibody Reduces Death in COVID-19 Patients Unable to Mount an Immune Response

BioSpace

?The new data shows REGEN-COV reduced the risk of death in hospitalized patients unable to mount their own immune response by 20%.

article thumbnail

Team studies immune response, proteins in blood of young adults who develop rare complication after COVID vaccination

Medical Xpress

In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine.